Top-Down Mass Spectrometry of a Clinical Antibody Light Chain Using the Omnitrap-Orbitrap-Booster Platform

30 July 2025, Version 1
This content is an early or alternative research output and has not been peer-reviewed by Cambridge University Press at the time of posting.

Abstract

The Omnitrap-Orbitrap-Booster (OOB) mass spectrometry (MS) platform was developed to advance top-down (TD) MS analysis of proteins. It integrates a multimodal tandem mass spectrometry (MS/MS) ion trap system (OmnitrapTM), a high-resolution Orbitrap Fourier transform mass spectrometer (FTMS), and a high-performance data acquisition system (FTMS Booster) to improve fragmentation efficiency and spectral quality by increasing the signal-to-noise (S/N) ratio of product ions. In this study, we evaluate the OOB platform for electron capture dissociation (ECD)-based TD MS analysis of a clinical multiple myeloma antibody light chain (P15), benchmarking its performance against the “gold-standard” electron transfer dissociation (ETD)-based TD MS on an Orbitrap EclipseTM. Single precursor charge state analysis yielded comparable sequence coverage (68.2% vs. 74.3%) between ECD-based TD MS on OOB and ETD-based TD MS on EclipseTM. Notably, ECD exhibits lower spectral peak density (i.e., reduced spectral congestion) due to reduced redundancy of product ions. Furthermore, leveraging multiple precursor charge states (15+ to 19+) analysis consecutively across triplicate LC-MS/MS run on the OOB platform enhances sequence coverage to 93%, demonstrating its capacity for comprehensive protein characterization. These results establish the OOB platform as a powerful and efficient tool for TD MS of proteins.

Keywords

monoclonal antibody
Electron Capture Dissociation
Absorption mode Fourier Transform
FTMS booster

Supplementary materials

Title
Description
Actions
Title
Supplementary information
Description
All supplementary figures
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting and Discussion Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.